O
OnKure Therapeutics, Inc. (OKUR)
3.99
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
3.99
0.00 (0.00%)
OnKure Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton va boshqa kasalliklarning biologik tasdiqlangan omillarini nishonga oluvchi aniq dorilarni kashf qilish va ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi OKI-219 ni o'z ichiga oladi, bu fosfoinozitid 3-kinaza alfa (PI3Kα) ning selektiv ingibitori bo'lib, H1047R mutatsiyasiga ega bo'lib, u ko'krak bezi saratoni kabi qattiq o'smalarni davolash uchun 1-bosqich klinik sinovdan o'tmoqda. Kompaniya 2011 yilda tashkil etilgan va shtab-kvartirasi Kolorado shtatining Bouldr shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | S-8 | okur-20260312.htm |
| 2025-11-06 | S-3 | d46696ds3.htm |
| 2025-06-26 | 8-K | okur-20250626.htm |
| 2025-05-28 | 8-K | okur-20250527.htm |
| 2025-04-16 | DEFA14A | ny20043636x2_defa14a.htm |
| 2025-03-20 | POS AM | d184865dposam.htm |
| 2025-03-10 | 8-K | okur-20250310.htm |
| 2024-12-09 | S-8 | okur_s-8_20241209_no_xbr.htm |
| 2024-10-28 | CORRESP | filename1.htm |
| 2024-10-23 | S-1 | d835714ds1.htm |
| Ms. Roberta Alton | Senior VP of Clinical Operations |